Negative / Null Result ReportOpen accessMedicine· cited by 35

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial

Pasquale F. Innominato; Abdoulaye Karaboué; C. Focan; P. Chollet; Sylvie Giacchetti; Mohamed Bouchahda; Ayhan Ulusakarya; Angela Torsello · 2020 · International Journal of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its circadian-based administration (chronoIFLO5) as either first- or second-line treatment, within the time-finding EORTC 05011 trial. Five-day chronoIFLO5 was administered every 3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan (180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil-leucovorin (2800 and 1200 mg/sqm, res

Abstract by Pasquale F. Innominato; Abdoulaye Karaboué; C. Focan; P. Chollet; Sylvie Giacchetti; Mohamed Bouchahda; Ayhan Ulusakarya; Angela Torsello, International Journal of Cancer (2020) — licensed CC BY 4.0.

Read the full paper (open access)